Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Fibrosis
Description
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury. MeSH
Hierarchy View
Subtype Terms (7)
Cicatrix
39 drugs (18 approved, 21 experimental)
Liver Cirrhosis
263 drugs (155 approved, 108 experimental)
Nephrogenic Fibrosing Dermopathy
5 drugs (4 approved, 1 experimental)
Pulmonary Fibrosis
44 drugs (31 approved, 13 experimental)
Radiation Fibrosis Syndrome
6 drugs (4 approved, 2 experimental)
Retroperitoneal Fibrosis
12 drugs (11 approved, 1 experimental)
Approved Indicated Drugs (1)
Phase 3 Indicated Drugs (28)
Other Experimental Indicated Drugs (24)
Organization Involved with Phase 4 Indications (198)
American Association for the Study of Liver Diseases Foundation
Asian Institute of Gastroenterology
Asian Institute Of Medical Sciences
Asian-Pacific Alliance of Liver Disease, Beijing
Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Badalona Hospital Germans Trias i Pujol
Canadian Cystic Fibrosis Foundation
CF Therapeutics Development Network Coordinating Center
China Academy of Chinese Medical Sciences
Cystic Fibrosis Foundation Therapeutics
Eastern Hepatobiliary Surgery Hospital
Fifth Hospital of Shijiazhuang City
German Federal Ministry of Education and Research
Good Samaritan Hospital, Cincinnati
Govind Ballabh Pant Institute of Postgraduate Medical Education and Research
Hannover Clinical Trial Center GmbH
Hospital Universitario Ramon y Cajal
Huai'an No. 4 People's Hospital
Huazhong University of Science and Technology
Hubei University of Chinese Medicine
Icahn School of Medicine at Mount Sinai
Institute of Liver and Biliary Sciences, India
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Instituto Nacional de la Nutrición Salvador Zubiran
Jining NO.1 People 's Hospital
Katholieke Universiteit Leuven
Laboratorios Senosiain, S.A. de C.V.
Medical University of South Carolina
National Health and Family Planning Commission, P.R.China
National Heart, Lung, and Blood Institute (NHLBI)
National Research Foundation of Korea
People's Liberation Army of China
Qilu Hospital of Shandong University
Samil Pharmaceutical Co., Ltd.
Second Military Medical University
Second People 's Hospital of Liaocheng
Shandong University of Traditional Chinese Medicine
Shanghai University of Traditional Chinese Medicine
Shenzhen Third People's Hospital
The Fifth People's Hospital of Suzhou
The Physicians' Services Incorporated Foundation
The University of Texas, Dallas
Universidad Autonoma de Barcelona
Universidad Complutense de Madrid
University of Alabama, Birmingham
University of California, Davis
University of California, Los Angeles
University of Campania Luigi Vanvitelli
University of Colorado, Denver
University of Naples Frederico II
University of Nice Sophia Antipolis
University of North Carolina at Chapel Hill
University of Roma La Sapienza
University of Southern California
University of Southern Denmark
Organization Involved with Phase 3 Indications (167)
All India Institute of Medical Sciences
AmpliPhi Biosciences Corporation
Assistance Publique - Hôpitaux de Paris
Association Francaise pour la Recherche Thermale
Associazione Italiana per la Ricerca sul Cancro
Bambino Gesù Hospital and Research Institute
Beijing Trendful Kangjian Medical Information Consulting Limited Company
Casa Sollievo della Sofferenza IRCCS
Case Western Reserve University
Centre Hospitalier Intercommunal Creteil
Cystic Fibrosis Federation Australia
European Cystic Fibrosis Society-Clinical Trial Network
F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
Federal University of Minas Gerais
Fondazione per la ricerca sulla Fibrosi Cistica
Fondo de Investigacion Sanitaria
French National Agency for Research on AIDS and Viral Hepatitis
Fundação de Amparo à Pesquisa do Estado de São Paulo
Funding for Research in Ophthalmology (FRO)
HIV-NAT Thai Red Cross AIDS Research Center
Hospital Universitario Virgen Macarena
Indian Council of Medical Research
Institut de Cancérologie de Lorraine
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Instituto Nacional de Cardiologia Ignacio Chavez
Interstitial Lung Disease Study Group, Korea
Istituto Clinico Humanitas - Rozzano (MI), Italy
Klinika Pneumonologii i Mukowiscydozy, Instytut Gruzlicy i Chorob Pluc w Rabce Zdroj
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health (NIH)
Pavol Jozef Safarik University
Postgraduate Institute of Medical Education and Research
Rio de Janeiro State University
Sociedad Andaluza de Enfermedades Infecciosas
Society for the Study of Liver Diseases, Chandigarh ( India )
TaiGen Biotechnology Co., Ltd.
Taipei Veteran General hospital
TaiwanJ Pharmaceuticals Co., Ltd
Telethon Institute for Child Health Research
The HIV Netherlands Australia Thailand Research Collaboration
The Oxford Dental College, Hospital and Research Center, Bangalore, India
Organization Involved with Phase 2 Indications (288)
A2 Healthcare Taiwan Corporation
ADS AIPHIA Development Services AG
Advanced Inhalation Therapies Ltd
Beijing Kawin Technology Share-Holding Co., Ltd.
Belgian Society against Cystic Fibrosis
Bharat Biotech International Limited
Bombay Hospital & Medical Research Center
Catholic University of Sacred Heart, Rome
Cell Therapy And Technology, S.a. De C.v.
Centre for Liver Research & Diagnostics, Hyderabad
Centro de Investigación Biomédica en Red (CIBER)
Chinese Academy of Medical Sciences
Chinese People's Armed Police Forces
CIHR Canadian HIV Trials Network
Coalition for Pulmonary Fibrosis
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Cook Children's Medical Center
Cumballa Hill Hospital And Heart Institute
Cyclacel Pharmaceuticals, Inc.
Daw Park Repatriation, Australia
Department of Health, United Kingdom
Department of Radiation Oncology
Desmond Wai Liver & Gastrointestinal Diseases Centre
Dunedin Public Hospital, New Zealand
Epidemiologie Pharmacologie Investigation Clinique Information medicale Mere Enfant
Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
General Hospital of Chinese Armed Police Forces
German Center for Lung Research
Global Blood Therapeutics, Inc.
Grupo Mexicano para el Estudios de las Enfermedades Hepaticas
Gwo Xi Stem Cell Applied Technology Co., Ltd.
Ho Chi Minh City University of Medicine and Pharmacy
Hoosier Cancer Research Network
IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest
Institut National de la Santé Et de la Recherche Médicale, France
Instituto Mexicano del Seguro Social
Instituto Nacional de Enfermedades Respiratorias
Japan Agency for Medical Research and Development
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Jiangsu Nhwa Pharmaceutical Co., Ltd.
Jingmen No.1 People’s Hospital
Kinderklinik und Kinderpoliklinik im Haunerschen Kinderspital
Life Mount Edgecombe Hospital, South Africa
Melaka Manipal Medical College
Midland Healthcare & Research Center, India
National Center for Global Health and Medicine
National Human Genome Research Institute (NHGRI)
National Institute for Health Research, United Kingdom
National University of Ireland
Niigata University Medical & Dental Hospital
Nordmark Arzneimittel GmbH & Co. KG
Oregon Health and Science University
P.D. Hinduja Hospital and Medical Research Centre, Mumbai
Queen Elizabeth Hospital NHS Foundation Trust
Radiation Therapy Oncology Group
Rainbow Baby and Children's Hospital
Rajasthan University of Health Sciences
Rajiv Gandhi University of Health Sciences
Rohto Pharmaceutical Co., Ltd.
Royal Marsden Hospital NHS Trust
San Giovanni Battista Hospital, Turin
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Shanghai Sundise Traditional Chinese Medicine Co., Ltd.
Smerud Medical Research Denmark
Southern California Research Center
Sri Bala Medical Centre and Hospital, India
St. Ivan Rilski's University Hospital
St Vincent's University Hospital, Ireland
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
SVS Institute of Dental Sciences
Swedish Cystic Fibrosis Association
Tauranga Hospital, New Zealand
The First People's Hospital of Lianyungang
Tokyo Metropolitan Komagome Hospital
Université catholique de Louvain
University of British Columbia
University of Illinois at Chicago
University of Las Palmas de Gran Canaria
University of Western Brittany
Via Christi Regional Medical Center
Organization Involved with Phase 1 Indications (62)
American College of Gastroenterology
Clinica Universidad de Navarra
Institute of Oncology Dr. Rosell (IOR)
Lester and Sue Smith Foundation
Northeast Ohio Medical University
Northern Ontario School of Medicine
Organization Involved with Other Experimental Indications (60)
Belgische Vereniging voor Strijd tegen Mucoviscidose
Canadian Institutes of Health Research (CIHR)
Cantonal Hospital of St. Gallen
Corporal Michael J. Crescenz VA Medical Center
Eurasia Invest Ltd., Kazakhstan
Government of British Columbia
Henan University of Traditional Chinese Medicine
Institut Hospital del Mar d'Investigacions Mèdiques
Instituto Nacional de Ciencias Medicas de Nutricion
National Cheng Kung University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Paddington Charitable Trust, London
Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Sociedad Chilena de Enfermedades Respiratorias
Spanish Clinical Research Network
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
